On January 7, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, reported that CEO, Dr James Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from 10-13 January 2022 (Press release, Kazia Therapeutics, JAN 7, 2022, https://www.prnewswire.com/news-releases/kazia-therapeutics-to-present-at-hc-wainwright-bioconnect-conference-301455376.html [SID1234598431]). The company has been invited to participate via a ‘fireside chat’ with a senior equity research analyst at the bank.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The HC Wainwright BioConnect Conference brings together more than 275 presenting companies from the life sciences sector, along with invited speakers and panellists. This year’s keynote speakers include Scott Gottlieb, MD, who was Commissioner of the Food and Drug Administration (FDA) between 2017 and 2019.
Dr Garner will participate in a fireside chat with Sean Lee, an equity research analyst at HC Wainwright. Dr Garner’s interview will be available via online streaming at the conference event platform from 7am (ET) on Monday, January 10, 2022. The interview is expected to cover an update on Kazia’s significant progress in 2021, and a discussion of the rich milestones anticipated in 2022.
Registration to the conference is free and is available via the conference website at:-